"Diabetes"

View all stories
article thumbnail

Five diabetes myths debunked

Get facts on five common falsehoods about diabetes

article thumbnail

Type 2 diabetes: A patient-centric approach to care

An informative Q&A with Dr. Sam Engel, associate vice president, cardiometabolic and women’s health at Merck Research Laboratories

article thumbnail

How Jeron’s type 2 diabetes diagnosis motivated him to live a healthy lifestyle

article thumbnail

The impact of family in managing type 2 diabetes

article thumbnail

America's Diabetes Challenge

article thumbnail

Merck to Present New Analyses for JANUVIA® (sitagliptin) and STEGLATRO™ (ertugliflozin), and Real-World Data Studies at the 79th Scientific Sessions of the American Diabetes Association

Real-World Evidence Research to Explore Socioeconomic, Racial and Ethnic Disparities in Diabetes Treatment KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that 25 studies, including new analyses for JANUVIA® (sitagliptin), STEGLATRO™ (ertugliflozin) and studies of real-world data, are scheduled to be presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, June 7 - 11, 2019. Presentations include new analyses of data with JANUVIA from the Comparative Trials with Sitagliptin (CompoSIT) program. New data for STEGLATRO, which was developed in collaboration with Pfizer, include analyses of its efficacy and safety profile in older adults with type 2 diabetes. “We look forward to sharing new clinical data and analyses across our broad diabetes portfolio, including studies focused on older adults with type 2 diabetes,” said Dr. Sam Engel, associate vice president, diabetes, endocrinology

article thumbnail

Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data from the Comparative Trials with Sitagliptin (CompoSIT) clinical trials with JANUVIA ® (sitagliptin). In the CompoSIT-I study, initiation of insulin therapy while continuing treatment with JANUVIA resulted in greater blood glucose reductions and more patients reaching A1C goal compared to those who discontinued JANUVIA. In the CompoSIT-R study, among patients with mild renal impairment inadequately controlled on metformin, with or without a sulfonylurea, treatment with JANUVIA showed non-inferiority and superiority in reducing A1C levels compared with patients treated with dapagliflozin. These results were presented at the 78 th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Florida. “Taken together, the results offer further insight into JANUVIA as a treatment option in these settings that impact substantial numbers of the type 2 diabetes patient population:

article thumbnail

Late-Breaking Data to be Presented from the Comparative Trials with Sitagliptin (CompoSIT) Program on the Continuation of JANUVIA® (sitagliptin) Treatment Among Patients Initiating Insulin Therapy

Merck to present new Phase 3 data on JANUVIA, STEGLATRO™ (ertugliflozin), and real-world evidence research at the 78th Scientific Sessions of the American Diabetes Association KENILWORTH, N.J., June 18, 2018 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that 31 studies from Merck’s diabetes portfolio – including new data for JANUVIA® (sitagliptin), STEGLATRO™ (ertugliflozin) and real-world research – will be presented at the 78th Scientific Sessions of the American Diabetes Association (ADA) in Orlando, June 22 - 26, 2018. Presentations include efficacy and safety data for JANUVIA in various settings across the treatment paradigm. Data on the long-term efficacy and safety of STEGLATRO, which was developed in collaboration with Pfizer, will also be presented. “We look forward to sharing new clinical data across our diabetes portfolio, which spans different and complementary mechanisms that may help address gaps in glycemic goal attainment,”

article thumbnail

Merck and Pfizer Announce That Investigational SGLT-2 Inhibitor Ertugliflozin Met Primary Endpoint in Two Phase 3 Studies

Ertugliflozin as Add-on to Metformin or in Initial Co-administration with Sitagliptin Showed Significant A1C Reductions in Adults with Type 2 Diabetes KENILWORTH, N.J. & NEW YORK - Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS MET and VERTIS SITA) of ertugliflozin, an investigational oral SGLT-2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes, met their primary endpoints. In the studies, both doses of ertugliflozin tested (5 mg and 15 mg daily) achieved statistically significant reductions in A1C, a measure of average blood glucose over a two- to three-month timeframe, when added to metformin or in initial co-administration with sitagliptin. The results of these studies, along with 52-week extension data from three other studies in the VERTIS clinical development program of ertugliflozin, will be presented at the 77th

article thumbnail

Recent Survey Finds Many Adults with Diabetes Unaware of Their Increased Risk for Certain Serious Illnesses

Findings Reinforce the Need for Greater Discussions Between Health Care Professionals and Patients to Help Them Understand Their Increased Risk For Pneumococcal Pneumonia/Pneumococcal Disease,Flu and Hepatitis B Many adults with diabetes are unaware of their increased risk for certain serious illnesses, including pneumococcal pneumonia/pneumococcal disease, flu and hepatitis B. This is according to a recent national, online consumer awareness survey sponsored by Merck (NYSE:MRK), known as MSD outside the United States and Canada, and the American Diabetes Association, and conducted by Harris Poll. In the survey of 1,003 U.S. adults ages 18 years and older diagnosed with diabetes, respondents were twice as likely to recognize the potential for adults with diabetes to develop kidney disease (72%) and heart disease (67%), than serious infectious diseases such as pneumococcal disease, including pneumonia, meningitis, or an infection of the blood (36%), compared to adults without diabetes.

article thumbnail

Merck Foundation Announces $10 Million Initiative to Improve Access to High-Quality Diabetes Care in Vulnerable and Underserved U.S. Communities

Non-Profit Organizations Invited to Apply for Grants to Improve Access to Diabetes Care The Merck Foundation (Foundation) announced today the launch of a new initiative, Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap), to improve access to high-quality diabetes care and reduce health disparities for vulnerable and underserved populations in the United States. With $10 million in funding from the Foundation over five years, Bridging the Gap will build sustainable partnerships across sectors to support innovative approaches to diabetes treatment and management. Bridging the Gap partners will work to ensure that individuals with diabetes can benefit not only from improved medical care, but also from interventions that address the multiple social and environmental factors outside of the health care system that influence health and well-being. “Diabetes is a significant population health concern, with more than 29 million Americans living with the disease. There